Impact of PINCH expression on survival in colorectal cancer patients

BMC Cancer

Volumn 11, Issue , 2011, Pages

  Lööf, Jasmine ^a   Rosell, Johan ^b   Bratthäll, Charlotte ^b   Doré, Siv ^c   Starkhammar, Hans ^b   Zhang, Hong ^a   Sun, Xiao Feng ^c  

^a UNIVERSITY OF SKÖVDE   (Sweden)

^b LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^c LINKÖPING UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; CAPECITABINE; EDRECOLOMAB; FLUOROURACIL; FOLINIC ACID; LEVAMISOLE; PROTEIN PINCH; UNCLASSIFIED DRUG; DNA BINDING PROTEIN; LIM PROTEIN; LIMS1 PROTEIN, HUMAN; MEMBRANE PROTEIN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TUMOR MARKER;

ADULT; AGE; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER LOCALIZATION; CANCER PATIENT; CANCER STAGING; COLON ADENOCARCINOMA; COLON MUCOSA; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PROTEIN EXPRESSION; SEX; SURVIVAL; TREATMENT RESPONSE; TUMOR DIFFERENTIATION; ADENOCARCINOMA; CELL DIFFERENTIATION; COLORECTAL TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; RETROSPECTIVE STUDY;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CELL DIFFERENTIATION; COLORECTAL NEOPLASMS; DNA-BINDING PROTEINS; FEMALE; HUMANS; LIM DOMAIN PROTEINS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 79953094759     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-11-103     Document Type: Article

References (54)

1. Rearden A. A new LIM protein containing an autoepitope homologous to "senescent cell antigen". Biochemical and biophysical research communications 1994, 201(3):1124-1131. 10.1006/bbrc.1994.1822, 7517666.
2. Dawid IB, Breen JJ, Toyama R. LIM domains: multiple roles as adapters and functional modifiers in protein interactions. Trends Genet 1998, 14(4):156-162. 10.1016/S0168-9525(98)01424-3, 9594664.
3. Hobert O, Moerman DG, Clark KA, Beckerle MC, Ruvkun G. A conserved LIM protein that affects muscular adherens junction integrity and mechanosensory function in Caenorhabditis elegans. J Cell Biol 1999, 144(1):45-57. 10.1083/jcb.144.1.45, 2148118, 9885243.
4. Tu Y, Li F, Goicoechea S, Wu C. The LIM-only protein PINCH directly interacts with integrin-linked kinase and is recruited to integrin-rich sites in spreading cells. Mol Cell Biol 1999, 19(3):2425-2434. 84035, 10022929.
5. Tu Y, Li F, Wu C. Nck-2, a novel Src homology2/3-containing adaptor protein that interacts with the LIM-only protein PINCH and components of growth factor receptor kinase-signaling pathways. Mol Biol Cell 1998, 9(12):3367-3382. 25640, 9843575.
6. Hannigan GE, Leung-Hagesteijn C, Fitz-Gibbon L, et al. Regulation of cell adhesion and anchorage-dependent growth by a new beta 1-integrin-linked protein kinase. Nature 1996, 379(6560):91-96. 10.1038/379091a0, 8538749.
7. Wang-Rodriguez J, Dreilinger AD, Alsharabi GM, Rearden A. The signaling adapter protein PINCH is up-regulated in the stroma of common cancers, notably at invasive edges. Cancer 2002, 95(6):1387-1395. 10.1002/cncr.10878, 12216108.
8. Gao J, Arbman G, Rearden A, Sun XF. Stromal staining for PINCH is an independent prognostic indicator in colorectal cancer. Neoplasia 2004, 6(6):796-801. 10.1593/neo.04304, 1531683, 15720806.
9. Zhang JT, Li QX, Wang D, et al. Up-regulation of PINCH in the stroma of oral squamous cell carcinoma predicts nodal metastasis. Oncol Rep 2005, 14(6):1519-1522.
10. Purdie CA, Piris J. Histopathological grade, mucinous differentiation and DNA ploidy in relation to prognosis in colorectal carcinoma. Histopathology 2000, 36(2):121-126. 10.1111/j.1365-2559.2000.00826.x, 10672056.
11. Li H, Fan X, Houghton J. Tumor microenvironment: the role of the tumor stroma in cancer. J Cell Biochem 2007, 101(4):805-815. 10.1002/jcb.21159, 17226777.
12. De Wever O, Mareel M. Role of tissue stroma in cancer cell invasion. J Pathol 2003, 200(4):429-447. 10.1002/path.1398, 12845611.
13. Fukuda T, Chen K, Shi X, Wu C. PINCH-1 is an obligate partner of integrin-linked kinase (ILK) functioning in cell shape modulation, motility, and survival. J Biol Chem 2003, 278(51):51324-51333. 10.1074/jbc.M309122200, 14551191.
14. Berrier AL, Yamada KM. Cell-matrix adhesion. J Cell Physiol 2007, 213(3):565-573. 10.1002/jcp.21237, 17680633.
15. Takada Y, Ye X, Simon S. The integrins. Genome Biol 2007, 8(5):215. 10.1186/gb-2007-8-5-215, 1929136, 17543136.
16. Chiarugi P, Giannoni E. Anoikis: a necessary death program for anchorage-dependent cells. Biochem Pharmacol 2008, 76(11):1352-1364. 10.1016/j.bcp.2008.07.023, 18708031.
17. Li Y, Dai C, Wu C, Liu Y. PINCH-1 promotes tubular epithelial-to-mesenchymal transition by interacting with integrin-linked kinase. J Am Soc Nephrol 2007, 18(9):2534-2543. 10.1681/ASN.2007030315, 17656471.
18. Thiery JP. Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 2003, 15(6):740-746. 10.1016/j.ceb.2003.10.006, 14644200.
19. Tsushima H, Kawata S, Tamura S, et al. High levels of transforming growth factor beta 1 in patients with colorectal cancer: association with disease progression. Gastroenterology 1996, 110(2):375-382. 10.1053/gast.1996.v110.pm8566583, 8566583.
20. Delcommenne M, Tan C, Gray V, Rue L, Woodgett J, Dedhar S. Phosphoinositide-3-OH kinase-dependent regulation of glycogen synthase kinase 3 and protein kinase B/AKT by the integrin-linked kinase. Proc Natl Acad Sci USA 1998, 95(19):11211-11216. 10.1073/pnas.95.19.11211, 21621, 9736715.
21. Takanami I. Increased expression of integrin-linked kinase is associated with shorter survival in non-small cell lung cancer. BMC Cancer 2005, 5:1. 10.1186/1471-2407-5-1, 546218, 15631637.
22. Marotta A, Tan C, Gray V, et al. Dysregulation of integrin-linked kinase (ILK) signaling in colonic polyposis. Oncogene 2001, 20(43):6250-6257. 10.1038/sj.onc.1204791, 11593435.
23. Dai DL, Makretsov N, Campos EI, et al. Increased expression of integrin-linked kinase is correlated with melanoma progression and poor patient survival. Clin Cancer Res 2003, 9(12):4409-4414.
24. Wu C, Keightley SY, Leung-Hagesteijn C, et al. Integrin-linked protein kinase regulates fibronectin matrix assembly, E-cadherin expression, and tumorigenicity. J Biol Chem 1998, 273(1):528-536. 10.1074/jbc.273.1.528, 9417112.
25. Radeva G, Petrocelli T, Behrend E, et al. Overexpression of the integrin-linked kinase promotes anchorage-independent cell cycle progression. J Biol Chem 1997, 272(21):13937-13944. 10.1074/jbc.272.21.13937, 9153256.
26. Koshida Y, Kuranami M, Watanabe M. Interaction between stromal fibroblasts and colorectal cancer cells in the expression of vascular endothelial growth factor. J Surg Res 2006, 134(2):270-277. 10.1016/j.jss.2006.02.025, 16600304.
27. Singer CF, Kronsteiner N, Marton E, et al. MMP-2 and MMP-9 expression in breast cancer-derived human fibroblasts is differentially regulated by stromal-epithelial interactions. Breast Cancer Res Treat 2002, 72(1):69-77. 10.1023/A:1014918512569, 12000221.
28. Tan C, Cruet-Hennequart S, Troussard A, et al. Regulation of tumor angiogenesis by integrin-linked kinase (ILK). Cancer Cell 2004, 5(1):79-90. 10.1016/S1535-6108(03)00281-2, 14749128.
29. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971, 285(21):1182-1186. 10.1056/NEJM197111182852108, 4938153.
30. Dassoulas K, Gazouli M, Theodoropoulos G, et al. Vascular endothelial growth factor and endoglin expression in colorectal cancer. J Cancer Res Clin Oncol 2009,
31. Weidner N. Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol 1995, 147(1):9-19. 1869874, 7541613.
32. Kitadai Y, Haruma K, Tokutomi T, et al. Significance of vessel count and vascular endothelial growth factor in human esophageal carcinomas. Clin Cancer Res 1998, 4(9):2195-2200.
33. Du JR, Jiang Y, Zhang YM, Fu H. Vascular endothelial growth factor and microvascular density in esophageal and gastric carcinomas. World J Gastroenterol 2003, 9(7):1604-1606.
34. Maeda K, Chung YS, Ogawa Y, et al. Prognostic value of vascular endothelial growth factor expression in gastric carcinoma. Cancer 1996, 77(5):858-863. 10.1002/(SICI)1097-0142(19960301)77:5<858::AID-CNCR8>3.0.CO;2-A, 8608475.
35. Troussard AA, Costello P, Yoganathan TN, Kumagai S, Roskelley CD, Dedhar S. The integrin linked kinase (ILK) induces an invasive phenotype via AP-1 transcription factor-dependent upregulation of matrix metalloproteinase 9 (MMP-9). Oncogene 2000, 19(48):5444-5452. 10.1038/sj.onc.1203928, 11114721.
36. Woessner JF. Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 1991, 5(8):2145-2154.
37. Westermarck J, Kahari VM. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 1999, 13(8):781-792.
38. Sato T, Sakai T, Noguchi Y, Takita M, Hirakawa S, Ito A. Tumor-stromal cell contact promotes invasion of human uterine cervical carcinoma cells by augmenting the expression and activation of stromal matrix metalloproteinases. Gynecol Oncol 2004, 92(1):47-56. 10.1016/j.ygyno.2003.09.012, 14751137.
39. Di Nezza LA, Misajon A, Zhang J, et al. Presence of active gelatinases in endometrial carcinoma and correlation of matrix metalloproteinase expression with increasing tumor grade and invasion. Cancer 2002, 94(5):1466-1475. 10.1002/cncr.10355, 11920503.
40. Kurahara S, Shinohara M, Ikebe T, et al. Expression of MMPS, MT-MMP, and TIMPs in squamous cell carcinoma of the oral cavity: correlations with tumor invasion and metastasis. Head Neck 1999, 21(7):627-638. 10.1002/(SICI)1097-0347(199910)21:7<627::AID-HED7>3.0.CO;2-2, 10487950.
41. Jones JL, Glynn P, Walker RA. Expression of MMP-2 and MMP-9, their inhibitors, and the activator MT1-MMP in primary breast carcinomas. J Pathol 1999, 189(2):161-168. 10.1002/(SICI)1096-9896(199910)189:2<161::AID-PATH406>3.0.CO;2-2, 10547569.
42. Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006, 69(3):562-573. 10.1016/j.cardiores.2005.12.002, 16405877.
43. Aglund K, Rauvala M, Puistola U, et al. Gelatinases A and B (MMP-2 and MMP-9) in endometrial cancer-MMP-9 correlates to the grade and the stage. Gynecol Oncol 2004, 94(3):699-704. 10.1016/j.ygyno.2004.06.028, 15350361.
44. Ruokolainen H, Paakko P, Turpeenniemi-Hujanen T. Expression of matrix metalloproteinase-9 in head and neck squamous cell carcinoma: a potential marker for prognosis. Clin Cancer Res 2004, 10(9):3110-3116. 10.1158/1078-0432.CCR-03-0530, 15131051.
45. Theret N, Musso O, Turlin B, et al. Increased extracellular matrix remodeling is associated with tumor progression in human hepatocellular carcinomas. Hepatology 2001, 34(1):82-88. 10.1053/jhep.2001.25758, 11431737.
46. Kaspar M, Zardi L, Neri D. Fibronectin as target for tumor therapy. Int J Cancer 2006, 118(6):1331-1339. 10.1002/ijc.21677, 16381025.
47. Danen EH, Yamada KM. Fibronectin, integrins, and growth control. J Cell Physiol 2001, 189(1):1-13. 10.1002/jcp.1137, 11573199.
48. Miyamoto S, Katz BZ, Lafrenie RM, Yamada KM. Fibronectin and integrins in cell adhesion, signaling, and morphogenesis. Ann N Y Acad Sci 1998, 857:119-129. 10.1111/j.1749-6632.1998.tb10112.x, 9917837.
49. Ioachim E, Charchanti A, Briasoulis E, et al. Immunohistochemical expression of extracellular matrix components tenascin, fibronectin, collagen type IV and laminin in breast cancer: their prognostic value and role in tumour invasion and progression. Eur J Cancer 2002, 38(18):2362-2370. 10.1016/S0959-8049(02)00210-1, 12460779.
50. Das S, Banerji A, Frei E, Chatterjee A. Rapid expression and activation of MMP-2 and MMP-9 upon exposure of human breast cancer cells (MCF-7) to fibronectin in serum free medium. Life Sci 2008, 82(9-10):467-476. 10.1016/j.lfs.2007.12.013, 18243246.
51. Maity G, Fahreen S, Banerji A, et al. Fibronectin-integrin mediated signaling in human cervical cancer cells (SiHa). Mol Cell Biochem 2009,
52. Bhardwaj B, Klassen J, Cossette N, et al. Localization of platelet-derived growth factor beta receptor expression in the periepithelial stroma of human breast carcinoma. Clin Cancer Res 1996, 2(4):773-782.
53. Kitadai Y, Sasaki T, Kuwai T, et al. Expression of activated platelet-derived growth factor receptor in stromal cells of human colon carcinomas is associated with metastatic potential. Int J Cancer 2006, 119(11):2567-2574. 10.1002/ijc.22229, 16988946.
54. Klintrup K, Makinen JM, Kauppila S, et al. Inflammation and prognosis in colorectal cancer. Eur J Cancer 2005, 41(17):2645-2654. 10.1016/j.ejca.2005.07.017, 16239109.